Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2

BMC Musculoskeletal Disorders

Volumn 5, Issue , 2004, Pages

  Tse, Raymond ^a,b   Howard, Jeffrey ^a,b   Wu, Yan ^a,b   Gan, Bing Siang ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; FASCIA; FIBROBLAST; HAND PALM; HUMAN; HUMAN CELL;

ANTIBODIES, ANTI-IDIOTYPIC; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DUPUYTREN CONTRACTURE; FIBROBLASTS; HUMANS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

EID: 12244294540     PISSN: 14712474     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-5-41     Document Type: Article

References (47)

1. Dupuytren G: Permanent retraction of the fingers, produced by an affection of the palmar fascia. Lancet 1834, 2:222-225.
2. Burge P: Genetics of Dupuytren's disease. Hand Clin 1999, 15:63-71.
3. Gabbiani G, Majno G: Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am J Pathol 1972, 66:131-146.
4. Bailey AJ, Sims TJ, Gabbiani G, Bazin S, LeLous M: Collagen of Dupuytren's disease. Clin Sci Mol Med 1977, 53:499-502.
5. Menzel EJ, Piza H, Zielinski C, Endler AT, Steffen C, Millesi H: Collagen types and anticollagen-antibodies in Dupuytren's disease. Hand 1979, 11:243-248.
6. Bazin S, Le Lous M, Duance VC, Sims TJ, Bailey AJ, Gabbiani G, D'Andiran G, Pizzolato G, Browski A, Nicoletis C, Delaunay A: Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Invest 1980, 10:9-16.
7. Gelberman RH, Amiel D, Rudolph RM, Vance RM: Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlative study. J Bone Joint Surg Am 1980, 62:425-432.
8. Brickley-Parsons D, Glimcher MJ, Smith RJ, Albin R, Adams JP: Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg [Am] 1981, 63:787-797.
9. Tomasek JJ, Schultz RJ, Episalla CW, Newman SA: The cytoskeleton and extracellular matrix of the Dupuytren's disease "myofibroblast": an immunofluorescence study of a nonmuscle cell type. J Hand Surg [Am] 1986, 11:365-371.
10. Tomasek JJ, Schultz RJ, Haaksma CJ: Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. J Bone Joint Surg [Am] 1987, 69:1400-1407.
11. Tomasek JJ, Haaksma CJ: Fibronectin filaments and actin microfilaments are organized into a fibronexus in Dupuytren's diseased tissue. Anat Rec 1991, 230:175-182.
12. Berndt A, Kosmehl H, Katenkamp D, Tauchmann V: Appearance of the myofibroblastic phenotype in Dupuytren's disease is associated with a fibronectin, laminin, collagen type IV and tenascin extracellular matrix. Pathobiology 1994, 62:55-58.
13. Halliday NL, Rayan GM, Zardi L, Tomasek JJ: Distribution of ED-A and ED-B containing fibronectin isoforms in Dupuytren's disease. J Hand Surg [Am] 1994, 19:428-434.
14. Magro G, Lanzafame S, Micali G: Co-ordinate expression of alpha 5 beta 1 integrin and fibronectin in Dupuytren's disease. Acta Histochem 1995, 97:229-233.
15. Baird KS, Crossan JF, Ralston SH: Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol 1993, 46:425-428.
16. Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D: TGF beta and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995, 27:1014-1020.
17. Zamora RL, Heights R, Kraemer BA, Erlich HP, Groner JP: Presence of growth factors in palmar and plantar fibromatoses. J Hand Surg [Am] 1994, 19:435-441.
18. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K: The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg [Am] 1996, 21:210-215.
19. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ: Transforming growth factor-beta: possible roles in Dupuytren's contracture. J Hand Surg [Am] 1995, 20:101-108.
20. Kuhn MA, Payne WG, Kierney PC, Pu LL, Smith PD, Siegler K, Ko F, Wang X, Robson MC: Cytokine manipulation of explanted Dupuytren's affected human palmar fascia. Int J Surg Investig 2001, 2:443-456.
21. Vaughan MB, Howard EW, Tomasek JJ: Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000, 257:180-189.
22. Varallo VM, Gan BS, Seney S, Ross DC, Roth JH, Richards RS, McFarlane RM, Alman B, Howard JC: Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003, 22:3680-3684.
23. Howard JC, Varallo VM, Ross DC, Roth JH, Faber KJ, Alman B, Gan BS: Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. BMC Musculoskelet Disord 2003, 4:16.
24. Howard JC, Varallo VM, Ross DC, Faber KJ, Roth JH, Seney S, Gan BS: Elevated expression of wound healing associated proteins Hsp-47 and fibronectin in Dupuytren's contracture. J Surg Res 2004, 117:232-238.
25. Montesano R, Orci L: Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing. Proc Natl Acad Sci U S A 1988, 85:4894-4897.
26. Fukamizu H, Grinnell F: Spatial organization of extracellular matrix and fibroblast activity: effects of serum, transforming growth factor beta, and fibronectin. Exp Cell Res 1990, 190:276-282.
27. Ignotz RA, Massague J: Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986, 261:4337-4345.
28. Ignotz RA, Endo T, Massague J: Regulation of fibronectin and type I collagen mRNA levels by transforming growth factorbeta. J Biol Chem 1987, 262:6443-6446.
29. Wang H, Chakrabarty S: Requirement of protein kinase Calpha, extracellular matrix remodeling, and cell-matrix interaction for transforming growth factorbeta- regulated expression of E-cadherin and catenins. J Cell Physiol 2001, 187:188-195.
30. Cheon SS, Nadesan P, Poon R, Alman BA: Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res 2004, 293:267-274.
31. ScionCorporation: http://www.scioncorp.com.
32. Cory AH, Owen TC, Barltrop JA, Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991, 3:207-212.
33. Berridge MV, Tan AS: Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993, 303:474-482.
34. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
35. Kuhn MA, Wang X, Payne WG, Ko F, Robson MC: Tamoxifen Decreases Fibroblast Function and Downregulates TGF(beta2) in Dupuytren's Affected Palmar Fascia. J Surg Res 2002, 103:146-152.
36. Letamendia A, Labbe E, Attisano L: Transcriptional regulation by Smads: crosstalk between the TGF-beta and Wnt pathways. J Bone Joint Surg Am 2001, 83-A Suppl 1:S31-9.
37. Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y, Kikuchi A, Miyazono K, Kato M: Axin facilitates Smad3 activation in the transforming growth factor beta signaling pathway. Mol Cell Biol 2001, 21:5132-5141.
38. Tian YC, Phillips AO: Interaction between the transforming growth factor-beta type II receptor/Smad pathway and beta-catenin during transforming growth factor-beta1-mediated adherens junction disassembly. Am J Pathol 2002, 160:1619-1628.
39. Schneider EL, Mitsui Y, Au KS, Shorr SS: Tissue-specific differences in cultured human diploid fibroblasts. Exp Cell Res 1977, 108:1-6.
40. Bordin S, Page RC, Narayanan AS: Heterogeneity of normal human diploid fibroblasts: isolation and characterization of one phenotype. Science 1984, 223:171-173.
41. Sorrell JM, Caplan AI: Fibroblast heterogeneity: more than skin deep. J Cell Sci 2004, 117:667-675.
42. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP: Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol 2003, 163:1291-1300.
43. Chipev CC, Simon M: Phenotypic differences between dermal fibroblasts from different body sites determine their responses to tension and TGFbeta1. BMC Dermatol 2002, 2:13.
44. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT: Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg 1999, 43:179-184.
45. Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M, Longaker MT: Differential expression of transforming growth factorbeta receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 2001, 108:423-429.
46. Wang X, Smith P, Pu LL, Kim YJ, Ko F, Robson MC: Exogenous transforming growth factor beta(2) modulates collagen I and collagen III synthesis in proliferative scar xenografts in nude rats. J Surg Res 1999, 87:194-200.
47. Smith P, Mosiello G, Deluca L, Ko F, Maggi S, Robson MC: TGF-beta2 activates proliferative scar fibroblasts. J Surg Res 1999, 82:319-323.